Medtronic (NYSE:MDT) Rating Increased to Buy at Wall Street Zen

Medtronic (NYSE:MDT) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Several other equities analysts have also recently weighed in on the company. Citigroup initiated coverage on Medtronic in a report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target on the stock. Sanford C. Bernstein increased their target price on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 target price on shares of Medtronic in a research report on Wednesday, November 19th. Daiwa Securities Group boosted their price target on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Finally, Leerink Partners lowered their price objective on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $111.05.

Medtronic Price Performance

MDT opened at $96.88 on Friday. The company’s 50-day simple moving average is $99.04 and its two-hundred day simple moving average is $96.65. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock has a market capitalization of $124.20 billion, a P/E ratio of 26.99, a P/E/G ratio of 2.45 and a beta of 0.71. Medtronic has a 52-week low of $79.55 and a 52-week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts predict that Medtronic will post 5.46 EPS for the current year.

Hedge Funds Weigh In On Medtronic

Hedge funds have recently modified their holdings of the company. Norges Bank bought a new position in Medtronic in the 4th quarter worth $1,653,485,000. Capital Research Global Investors boosted its stake in shares of Medtronic by 12.6% in the fourth quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after acquiring an additional 3,880,174 shares during the period. Barclays PLC grew its position in shares of Medtronic by 104.6% during the third quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock worth $650,604,000 after purchasing an additional 3,492,192 shares in the last quarter. Schroder Investment Management Group raised its stake in Medtronic by 78.3% during the 3rd quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after purchasing an additional 3,307,211 shares during the period. Finally, Guinness Asset Management LTD bought a new stake in Medtronic during the 3rd quarter valued at approximately $275,556,000. 82.06% of the stock is currently owned by institutional investors.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory/coverage win in Japan for Medtronic’s Symplicity Spyral renal denervation device and management commentary that the company is investing in rollout and hiring to support market development — supports revenue upside from a growing hypertension therapy. Medtronic’s blood pressure device wins coverage nod in Japan
• Positive Sentiment: Analyst upgrade: Mizuho moved Medtronic to a “strong-buy,” which can support buying interest and short-term momentum. Mizuho upgrade reported via Zacks
• Neutral Sentiment: Industry growth tailwinds — a separate report highlights expansion in non‑invasive therapies (HIFU) and robotics/image‑guided systems; positive for device sector demand but not a direct Medtronic headline. HIFU Market Competitive Landscape Report 2025
• Neutral Sentiment: Competitive update — Intuitive Surgical (ISRG) reports faster international procedure growth, which underscores competitive dynamics in robotics and could pressure Medtronic’s robotics expectations over time. ISRG’s International Growth Outpaces US
• Neutral Sentiment: Company commentary and Q3 earnings materials are out (transcript available) showing mixed results: solid robotics wins but offset by some legal and expense items — provides context for guidance and valuation debate. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Multiple broker notes lowered expectations or targets (JPMorgan, Robert W. Baird; Leerink cut its target to $119) — analyst downgrades/target cuts weigh on sentiment and can amplify selling. JPMorgan low expectations
• Negative Sentiment: Planned layoffs: Medtronic will cut 81 roles at a California diabetes site as it readies the diabetes spin‑out; restructuring adds near‑term execution risk and uncertainty around the separations. Medtronic to cut 81 employees at California diabetes site
• Negative Sentiment: Broader skepticism in media pieces discussing mixed quarterly results, legal exposure and whether recent wins materially change Medtronic’s investment case — fuels analyst disagreement and investor caution. Mixed Q3 Results, Robotics Win and Legal Hit

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).